Switch over from intravenous to oral therapy: A concise overview

Jissa Maria Cyriac, Emmanuel James
Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Health Science Campus, Amrita Vishwa Vidyapeetham University, Ponekkara, Kochi, Kerala, India

ABSTRACT

Majority of the patients admitted to a hospital with severe infections are initially started with intravenous medications. Short intravenous course of therapy for 2-3 days followed by oral medications for the remainder of the course is found to be beneficial to many patients. This switch over from intravenous to oral therapy is widely practiced in the case of antibiotics in many developed countries. Even though intravenous to oral therapy conversion is inappropriate for a patient who is critically ill or who has inability to absorb oral medications, every hospital will have a certain number of patients who are eligible for switch over from intravenous to oral therapy. Among the various routes of administration of medications, oral administration is considered to be the most acceptable and economical method of administration. The main obstacle limiting intravenous to oral conversion is the belief that oral medications do not achieve the same bioavailability as that of intravenous medications and that the same agent must be used both intravenously and orally. The advent of newer, more potent or broad spectrum oral agents that achieve higher and more consistent serum and tissue concentration has paved the way for the popularity of intravenous to oral medication conversion. In this review, the advantages of intravenous to oral switch over therapy, the various methods of intravenous to oral conversion, bioavailability of various oral medications for the switch over program, the patient selection criteria for conversion from parenteral to oral route and application of intravenous to oral switch over through case studies are exemplified.

Key words: Economic impact, intravenous to oral, parenteral medication, switch over

INTRODUCTION

The ideal route of administration of any medication is the one that achieves serum concentrations sufficient to produce the desired effect without producing any untoward effects.[1] Safest and convenient way of medication administration is achieved by oral route. If the given oral medication achieves tissue and blood concentration to the same extent as that of the intravenous (IV) medication, then there is little therapeutic difference between IV and oral medications.[2] The available oral formulations in the market are easier to administer, safe and achieve desired therapeutic concentrations, thus making the per oral (PO) route an ideal choice.[1,3]

World Health Organization (WHO) reports that the irrational use of medicines is a major problem worldwide.[4] The over-use of injections, when oral formulations would be more appropriate, is one of the key factors for the irrational use of medicines. Hence IV to oral switch over within an appropriate
time is one of the major aspects to improve the rational use of injections. Moreover, once the culture and sensitivity reports are available, IV to oral switch over enables one to select a cheaper or older antibiotic, which is as effective as the IV antibiotic. This has significance in the light of the WHO world health day theme, 2011: ‘Anti-microbial resistance: No action today, no cure tomorrow’. [5]

Bioavailability of IV medications is always higher than that of their oral counterpart, so that the patient may get relief from symptoms earlier if they receive a complete IV course of therapy, is a concept that is popular among the physicians. [6] But the fact is that for a large number of medications, essentially the same amount of drug is found in the blood when given intravenously or orally. Moreover, they believe that chances of reinfection will be less if they give a complete IV course of antibiotics. [2] As a result, physicians usually tend to opt for the IV medications at the time of admission and continue them till patient discharge.

In the Indian scenario, the concept of early switch over from IV to oral therapy is not common even though it is popular in Western countries. [7‑9] A study carried out by Palanisamy and colleagues in the general medicine department of a 450 bedded tertiary care hospital in south India for a period of 6 months showed that the average cost of antibiotics and the length of stay of patients could be reduced due to early switch over from parenteral to oral therapy. [10] A new approach to carry out the IV to oral switch over is to establish a computerized intervention. Patient’s data along with details of medications received are entered into a computer and on every day at midnight, the computer compiles a list of patients who are matching with selection criteria for switch over. Pharmacist takes the print out of the list and discusses with the physician for switch over according to the clinical status of the patient. [6,11]

Most of the studies related to IV to PO conversions have been restricted to certain antibiotic and certain medical condition like respiratory tract infections. [12,13] Only a few studies have been done to assess physician’s knowledge, beliefs and acceptance of the switch over from IV to oral therapy. [2] Antibiotics, gastrointestinal agents (mainly proton pump inhibitors and histamine-2 antagonists), and antifungals are major medication classes that can be utilized in IV to oral switch over. [11] In many of the advanced hospitals in developed countries, fluoroquinolones are the predominant drug class which is commonly involved in switch over program. [12,14] The drugs such as metronidazole, azithromycin, and linezolid are also involved in IV to PO conversion program. Less commonly, doxycycline, and trimethoprim/sulphamethoxazole are also involved in switch over. In the case of antifungals, fluconazole and itraconazole are the two major drugs involved in switch over from IV to oral. [11] Various drug classes involved in IV to oral conversion, in the ascending order of preference, are Diuretics < Corticosteroids < Analgesics < Antivirals < Cardiovascular agents < Antifungals < GI agents < Antibacterials. [11]

Advantages of oral over IV route

Early switch over from IV to oral therapy has the following major advantages:

• Reduced risk of cannula-related infections: For the administration of IV medications, one is required to insert a cannula, which remains in place for some days and eventually can result in secondary infections caused by bacteria and fungi. This may ultimately lead to the need for additional antibiotics and subsequently financial burden to the patient. [5]

• Risk of thrombophlebitis: No risk of thrombophlebitis in case of oral administration. [1,3,11]

• Less expensive than IV therapy: Most of the oral medications available at the market are less expensive as the parenteral medications must be sterile and isotonic, consequently leading to cost savings by the patient. [1,13,16]

• Reduction in the hidden costs: Hidden costs mainly refer to cost of diluents, equipments for administration, needles, syringes, and nursing time. Needles, syringes, diluents, and other equipments are the unavoidable requisites for the parenteral administration. Above all, an experienced professional must be there to administer the injection. As a result, it may cause a financial burden for the patient and take away valuable nursing time for patient-care. [1,13,16]

• Earlier discharge: Injections are usually administered in a hospital setting as it requires an experienced professional to administer the medication, especially IV infusions. Hence the patient stay at the hospital is prolonged. Early switch over to oral medications can help to overcome this barrier and may result in early discharge of the patient. [3]

Types of IV to oral conversions

There are mainly three types of IV to PO conversions. [1]

• Sequential therapy: It refers to the act of replacing a parenteral version of a medication with its oral counterpart of the same compound. For instance, conversion of inj. pantoprazole 40 mg OD (once daily) to tab. pantoprazole 40 mg OD. [16]

• Switch therapy: It describes the conversion of an IV medication to a PO equivalent; within the same class and has the same level of potency, but of a different compound. For example, switch over from inj. ceftriaxone 1 g BD (bis in die) to tab. cefixime 200 mg BD. [17] switch over from inj. pantoprazole 40 mg BD to tab. rabeprazole 20 mg BD.

• Step down therapy: It refers to the conversion from an injectable medication to an oral agent in another class or to a different medication within the same class where the frequency, dose, and the spectrum of activity (in the case of antibiotics) may not be exactly the same. For example, conversion of inj. cefotaxim 1 g to tab. ciprofloxacin 500 mg, switch over from inj. heparin to tab. warfarin.
Practical approaches for conversion of a patient from IV to oral therapy

Establishment of an IV to oral switch over program at a hospital is the stepping stone toward the successful conversion of a patient from IV to oral therapy. It is the sole responsibility of a clinical pharmacist to establish such a guideline with the approval of the Pharmacy and Therapeutics committee of the hospital and ensure that the conversion is done in tune with the guideline.[1,2,18]

- First, a clinical pharmacist should identify patients who receive IV medications and also recognize the need for IV medication in those patients and check for the indication.
- Second, regular follow-up is needed to check whether the patient’s clinical status (WBC [white blood cells], vitals, culture report, patient’s physical and mental condition, etc.) is improving or not. If the patient is eligible for conversion [Table 3], check whether the conversion was done.
- Inform the physician about the patients who are eligible for conversion but not converted within the appropriate time.
- Make suitable recommendations for the selection of an oral medication for conversion.
- Review the feedback of the physicians.
- Monitor the patient’s clinical progress after the switch over and convert the patient back to parenteral medication, if required.
- It is always advisable to verify the knowledge and beliefs of physicians regarding the guideline for switch over from IV to oral therapy. A data collection tool like questionnaires can be used for the same.

The patient selection criteria for IV to oral switch therapy[1,19,21] is given in Table 3.

Bioavailability of medications included in IV to oral conversion

Usually 100% bioavailability is assured only for IV medications and not for other routes like intramuscular or subcutaneous route. When a medication is administered intravenously it can directly reach the blood circulation and thereby assure 100% bioavailability. To be effective, oral antibiotics must achieve serum bactericidal activity almost comparable to that of its IV counterpart.[1,9] Table 1 explains the examples of IV to oral switch over for medications with >90% bioavailability. Examples of drugs with good bioavailability (60-90%) eligible[19,20] for IV to oral switch over are given in Table 2.

Therapeutic application of IV to oral switch over: Special focus on some common disease conditions

Community-acquired pneumonia

About 40-60% of patients admitted with community-acquired pneumonia are eligible for switch over within 2-3 days of treatment.[11] Vital signs and WBC should be monitored before conversion from IV to oral therapy. Fluoroquinolones are the first line drugs for the treatment of community-acquired pneumonia. Study which compared IV/PO moxifloxacin with IV/PO amoxicillin-clavulanate with or without clarithromycin proved that moxifloxacin is rated at a higher percentage of clinical cure.[22]

The following case illustrates an IV to PO conversion done at the appropriate time:

- A 52-year-old female admitted to the general ward of a hospital with cough and breathing difficulty was treated empirically with inj. Cefoperazone – sulbactam 2 g BD and tab. levofloxacin 500 mg OD. She was also started on inj. pantoprazole 40 mg BD and inj. neurobion forte® (vitamin B1, B6 and B12) OD. Her vitals and WBC counts became normal from the third day of admission. Later

| Table 1: Examples of drugs with excellent bioavailability (>90%) eligible for IV to oral switch over |
| --- |
| **Drugs** | **IV to PO conversion** | **PO dose** |
| Ciprofloxacin* | 200 mg q12h (every 12 hours) | 500 mg q12h |
| Doxycycline | 100-200 mg q12h | 100-200 mg q12h |
| Esomeprazole | 20-40 mg q24h | 20-40 mg q24h |
| Fluconazole | 100-200 mg q24h | 100-200 mg q24h |
| Hydrocortisone | 100 mg q24h | 50 mg q8h |
| Ketorolac | 30 mg q24h | 20 mg q24h |
| Levetiracetam | 500 mg q12h | 500 mg q12h |
| Levofloxacin* | 500 mg q24h | 500 mg q24h |
| Linezolid | 600 mg q12h | 600 mg q12h |
| Metronidazole | 500 mg q12h | 500 mg q12h |
| Minocycline | 200 mg q12h | 200 mg q12h |
| Moxifloxacin* | 400 mg q24h | 400 mg q24h |
| Phenytoin | 100 mg q8h | 100 mg q8h |
| Rifampicin | 600 mg q24h | 600 mg q24h |
| Voriconazole | 200 mg q24h | 200 mg q24h |

*Absorption of fluoroquinolones is reduced by concurrent administration of products containing divalent and trivalent cations such as calcium, magnesium or aluminum, for example, antacids, multivitamin products containing minerals, iron, or zinc salts. Hence an interval of at least 4 hours should elapse between their oral administration.

| Table 2: Examples of drugs with good bioavailability (60-90%) eligible for IV to oral switch over |
| --- |
| **Drugs** | **IV dose** | **IV to PO conversion** | **PO dose** |
| Ampicillin | 1 gm q8h | 250-500 mg q6h |
| Azithromycin | 500 mg q24h | 250-500 mg q24h |
| Cefazolin | 1 gm q12h | Tab. cephalaxin 500 mg q6h |
| Cefotaxime | 1 gm q12h | Tab. ciprofloxacin 500-750 mg q12h |
| Ceftazidime | 1-2 g q8h | Tab. ciprofloxacin 500-750 mg q12h |
| Cimetidine | 300-600 mg q12h | 200 mg q12h |
| Cefuroxime | 500-750 gm q8h | Tab. ceftizoxime axetil 250-500 mg q12h |
| Clindamycin | 300-600 mg q8h | 300-450 mg q6h |
| Digoxin | 0.1-0.4 mg q24h | 0.125-0.5 mg q24h |
| Erythromycin | 500-1000 mg q6h | 500 mg q6h |
| Pantoprazole | 40 mg q24h | 40 mg q24h |
Table 3: Patient selection criteria for IV to oral switch over therapy

| Inclusion criteria                                                                 | Exclusion criteria                                                                 |
|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Patient is able to eat their regular or modified diet or receiving enteral nutrition by oral, gastric or other appropriate enteral route Patient receives other scheduled oral medications | Patients with unreliable response to oral medications (severe nausea or vomiting) |
| For patients who receive antibiotics, signs and symptoms of infection resolved or improving (WBC decreasing toward normal range, improving chest X-ray findings, temperature less than 100°F for at least 24-48 hours and respiratory rate <20 breaths/min.) | Unable to swallow or unconscious |
| Patient has functional gastrointestinal tract (tolerating at least 1 liter/day of oral fluids or 40 ml/hour of enteral nutrition) An appropriate oral dosage form of prescribed drug is available Absorption and bioavailability of oral counterpart is almost comparable to that of parenteral form | Strict (nothing per oral) for a procedure GI obstruction, malabsorption, active GI bleeding, paralytic ileus or severe diarrhea |

Note: If the patient has one or more symptoms listed under exclusion criteria, then not suitable for switch over from IV to oral medications. WBC=White blood cells, NPO=Nothing per oral, AIDS=Acquired immunodeficiency syndrome

Her sputum culture showed growth of *Candida albicans*. She was then started on tab. fluconazole 100 mg BD for 10 days and inj. cefoperazone-sulbactam was stopped, but tab. levofloxacin was continued till discharge. All the other parenteral medications were switched over to the oral form from the third day of admission (inj. pantoprazole to tab. pantoprazole 40 mg OD and inj. neubion forte® to tab. neubion forte® OD). The patient’s condition improved with the oral medications.

**Infectious diarrhea/typhoid (enteric) fever**

Acute watery diarrhea is mainly caused by the pathogens *Escherichia coli, campylobacter, salmonella* or *vibrio* species. The preferred therapy is a quinolone IV or PO for 5 days. Both IV and oral formulations of quinolones have same bioavailability.¹²³⁴

- A 28-year-old male admitted for acute gastroenteritis was started on ciprofloxacin 200 mg IV 12 hourly and metronidazole 500 mg IV 8 hourly. He was also started on the same day inj. pantoprazole 40 mg 1-0-1, tab. raccadotril 100 mg 1-1-1 and paracetamol 650 mg prn. From the second day his diarrhea and vomiting subsided and was able to take oral food. His vitals became normal on the third day of admission and WBC count was 9730/µl. It is possible to switch over the IV medications of this patient to the equivalent oral forms at the earliest [Table 1].

**CONCLUSION**

Large array of medications are suitable for conversion from IV to oral therapy and various types of IV to oral conversions are possible. There are various guidelines available in this regard and each hospital should implement such a guideline at the initiation of a clinical pharmacist in order to accomplish an ideal IV to PO conversion therapy. The clinical pharmacist should thoroughly review the medical records and identify patients who are eligible for parenteral to oral therapy conversion. In the Indian scenario, we have yet to accomplish an ideal IV to PO conversion program in our day-to-day clinical practice.

**REFERENCES**

1. Kuper KM. Intravenous to oral therapy conversion. Text Book of Competence Assessment Tools for Health-System Pharmacies, 4th ed. ASHP 2008. p. 347-60.
2. Lee SL, Azmi S, Wong PS. Clinicians’ knowledge, beliefs and acceptance of intravenous-to-oral antibiotic switching. Hospital Pulau Pinang. Med J Malaysia 2012;67:190-8.
3. Sevinc F, Prins JM, Koopmans RP, Langendijk PN, Bossuyt PM, Dankert J, et al. Early switch from intravenous to oral antibiotics: Guidelines and implementation in a large teaching hospital. J Antimicrob Chemother 1999;43:601-6.
4. The pursuit of responsible use of medicines: Sharing and learning from country experiences. Available from: www.who.int/medicines/areas/rationaluse/en/. [Last accessed on 2013 Jun 29; Last updated on 2013 Jun 22].
5. World Health Day 2011 - Antibiotic resistance: No action today, no cure tomorrow. Available from: www.euro.who.int. [Last accessed on 2013 Jun 29].
6. Fischer MA, Solomon DH, Teich JM, Avorn J. Conversion from intravenous to oral medications: Assessment of a computerized intervention for hospitalized patients. Arch Intern Med 2003;163:2583-9.
7. Cunha BA. Intravenous-to-oral antibiotic switch therapy. A cost-effective approach. Postgrad Med 1997;101:111-2.
8. McMauglin CM, Bodasing N, Boyer AC, Fendol C, Fox JG, Seaton RA. Pharmacy-implemented guidelines on switching from intravenous to oral antibiotics: An intervention study. QJM 2005;98:745-52.
9. Gwawali S, Shankar PR, Saha A, Mohan L. Study of prescription of injectable drugs and intravenous fluids to inpatients in a teaching hospital in Western Nepal. MCGill J Med 2009;12:13-20.
10. Palanisamy A, Narmatha MP, Rajendran NN, Rajalingam B, Siriram S. Conversion of intravenous-to-oral antimicrobial therapy in South Indian population. IJRPBS 2011;2:1258-60.
11. Banko H, Goldwater SH, Adams E. Smoothing the path for intravenous (IV)
to oral (PO) conversion: Where have we come in 11 years? Hosp Pharm 2009;44:959-67.
12. Cunha BA. Oral versus IV treatment for catheter-related bloodstream infections. Emerg Infect Dis 2007;13:1800-1.
13. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72.
14. Castro-Guardiola A, Viejo-Rodríguez AL, Soler-Simon S, Armengou-Araé A, Bisbe-Company V, Peñarroja-Matutano G, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: A randomized controlled trial. Am J Med 2001;111:367-74.
15. Jensen KM, Paladino JA. Cost-Effectiveness of abbreviating the duration of intravenous antibacterial therapy with oral fluoroquinolones. Pharmacoeconomics 1997;11:64-74.
16. Galanter W, Liu XF, Lambert BL. Analysis of computer alerts suggesting oral medication use during computerized order entry of iv. medications. Am J Health Syst Pharm 2010;67:1101-5.
17. Hamilton-Miller JM. Switch therapy: The theory and practice of early change from parenteral to non-parenteral antibiotic administration. Clin Microbiol Infect 1996;2:12-9.
18. NHS Grampian medicines management. Available from: http://www.nhsgrampian.com/grampianfoi/files/NHSIVOST.pdf. [Last accessed on 2013 Jun 29; Last updated on 2012 Jun].
19. Wetstein GA. Intravenous to oral (iv: po) anti-infective conversion therapy. Cancer Control 2000;7:170-6.
20. IV to oral conversion program. Available from: http://legacy.uspharmacist.com/oldformat.asp?url=newlook/files/Feat/ACF3023.cfm. [Last accessed on 2013 Jun 29; Last updated on 2013 Jun 20].
21. Zamin MT, Ptre MM, Corly JM. Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility. Ann Pharmacother 1997;31:564-70.
22. Lee RW, Lindstrom ST. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. Respirology 2007;12:111-6.
23. Janknegt R, van der Meer JW. Sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother 1994;33:169-77.
24. Cunha BA. Text book of essentials of antibiotic prescribing, 10th ed. USA: Jones and Bartlett Publishers; 2011. p. 10-25.

How to cite this article: Cyriac JM, James E. Switch over from intravenous to oral therapy: A concise overview. J Pharmacol Pharmacother 2014;5:83-7.

Source of Support: Nil. Conflict of Interest: None declared.

Announcement

“QUICK RESPONSE CODE” LINK FOR FULL TEXT ARTICLES

The journal issue has a unique new feature for reaching to the journal’s website without typing a single letter. Each article on its first page has a “Quick Response Code”. Using any mobile or other hand-held device with camera and GPRS/other internet source, one can reach to the full text of that particular article on the journal’s website. Start a QR-code reading software (see list of free applications from http://tinyurl.com/yahl2tc) and point the camera to the QR-code printed in the journal. It will automatically take you to the HTML full text of that article. One can also use a desktop or laptop with web camera for similar functionality. See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free applications.